Mindset Pharma (CNSX:MSET) - Prezzo delle azioni, notizie e analisi

MSET Panoramica delle azioni

Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. Maggiori dettagli

MSET analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 43.75% all'anno

I ricavi sono cresciuti del 242.5% nell'ultimo anno

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 22% all'anno per i prossimi 3 anni

Patrimonio netto negativo

Ha meno di 1 anno di pista di cassa

Non ha una capitalizzazione di mercato significativa ( CA$75M )

+ 2 più rischi

Mindset Pharma Inc. Concorrenti

InnoCan Pharma

CNSX:INNO

CA$60.3m

1CM

CNSX:EPIC

CA$29.4m

YourWay Cannabis Brands

CNSX:YOUR

CA$23.2m

Greenway Greenhouse Cannabis

CNSX:GWAY

CA$64.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Mindset Pharma
Prezzi storici delle azioni
Prezzo attuale dell'azione	CA$0.74
Massimo di 52 settimane	CA$0.75
Minimo di 52 settimane	CA$0.22
Beta	-0.098
1Variazione di 1 mese	1.37%
Variazione a 3 mesi	45.10%
Variazione di 1 anno	76.19%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-26.00%

Notizie e aggiornamenti recenti

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Jun 02

Recent updates

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Jun 02

Companies Like Mindset Pharma (CSE:MSET) Can Afford To Invest In Growth

Sep 18

We're Interested To See How Mindset Pharma (CSE:MSET) Uses Its Cash Hoard To Grow

Jun 05

Rendimenti per gli azionisti

	MSET	CA Pharmaceuticals	CA Mercato
7D	-1.3%	-6.9%	2.2%
1Y	76.2%	-22.8%	23.4%

Ritorno vs Industria: MSET ha superato il Canadian Pharmaceuticals che ha restituito -22.8 % nell'ultimo anno.

Rendimento vs Mercato: MSET ha superato il mercato Canadian che ha restituito 23.4 % nell'ultimo anno.

Volatilità dei prezzi

Is MSET's price volatile compared to industry and market?
MSET volatility
MSET Average Weekly Movement	6.6%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	2.9%

Prezzo delle azioni stabile: Il prezzo delle azioni di MSET è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di MSET è diminuita da 13% a 7% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	n/a	James Lanthier	www.mindsetpharma.com

Mindset Pharma Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Mindset Pharma con la sua capitalizzazione di mercato?
MSET statistiche fondamentali
Capitalizzazione di mercato	CA$74.96m
Guadagni(TTM)	-CA$6.11m
Ricavi(TTM)	CA$7.75m

9.7x

Rapporto P/S

-12.3x

Rapporto P/E

MSET è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MSET Conto economico (TTM)
Ricavi	CA$7.75m
Costo del fatturato	CA$0
Profitto lordo	CA$7.75m
Altre spese	CA$13.86m
Guadagni	-CA$6.11m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.06
Margine lordo	100.00%
Margine di profitto netto	-78.82%
Rapporto debito/patrimonio netto	0%

Come si è comportato MSET nel lungo periodo?

Vedi performance storica e confronto

MSET Panoramica delle azioni

Premi

Analisi del rischio

Mindset Pharma Inc. Concorrenti

CNSX:INNO

CA$60.3m

CNSX:EPIC

CA$29.4m

CNSX:YOUR

CA$23.2m

CNSX:GWAY

CA$64.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc. (CNSX:MSET).

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

New major risk - Financial position

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Mindset Pharma Inc., Annual General Meeting, Mar 17, 2023

Recent updates

Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc. (CNSX:MSET).

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

New major risk - Financial position

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Mindset Pharma Inc., Annual General Meeting, Mar 17, 2023

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Mindset Pharma Inc. Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate

Mindset Pharma Inc., Annual General Meeting, Feb 24, 2023

High number of new and inexperienced directors

Mindset Pharma Presents Poster At Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, Its Psilocybin-Like Lead Drug Candidate

Mindset Pharma Inc. Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Companies Like Mindset Pharma (CSE:MSET) Can Afford To Invest In Growth

Mindset Pharma Inc. Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries

Mindset Pharma Inc. Announces it Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds

High number of new and inexperienced directors

Mindset Pharma Inc. Announces Development of Novel, Optimized, Intranasal Formulation

We're Interested To See How Mindset Pharma (CSE:MSET) Uses Its Cash Hoard To Grow

Mindset Pharma Inc. Progresses Plans for Clinical Trials of Its Advanced Pre-Clinical Psychedelic, Msp-1014

Independent Chairman recently bought CA$52k worth of stock

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

Mindset Pharma Inc Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

Mindset Pharma Inc Appoints Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy

Independent Chairman recently bought CA$102k worth of stock

Mindset Pharma Inc. announced that it has received $5 million in funding from McQuade Center for Strategic Research and Development, LLC

Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in Its Long-Acting Next Generation Psychedelic Compounds

Mindset Pharma Inc. Files its New Provisional Patent Application with the United States Patent and Trademark Office Extending its Family 4 Compounds, Set of Novel DMT/5-MeO-DMT Analogs

Mindset Pharma Inc. Files International Patent Application for Its Novel Psilocybin Synthesis Method

Chairman & Director recently bought CA$66k worth of stock

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Director recently bought CA$75k worth of stock

Mindset Pharma Inc. Files Sixth U.S. Provisional Patent, Expanding its Psychedelic Drug Candidates Pipeline with Novel DMT & 5-MeO-DMT Analogs

Mindset Pharma Inc. Appoints Joseph Gabriele to Scientific Advisory Board

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

Mindset Pharma Inc. Announces New Drug Program with Proof-Of-Concept Animal Studies of its Patent-Pending Psilocybin-Inspired Drug Candidates

Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in Vivo Poc Studies

Mindset Pharma Inc. Expands Portfolio of Psychedelic Drug Candidates with Third U.S. Provisional Patent Application

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Mindset Pharma Inc. Riepilogo dei fondamenti

9.7x

-12.3x

Guadagni e ricavi